The National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, has awarded a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to acquire Genome Characterization Center (GCC) services. The contract, valued at up to $149,974,285, has a period of performance through January 2030. The GCC services include large-scale, high-resolution, and comprehensive sequencing and array platforms, such as whole exome sequencing, to support...
This Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. Department of Health and Human Services, to The Washington University's Office of Sponsored Research Services Division. The contract is for Genome Characterization Center (GCC) services, which involve large-scale, high-resolution, and comprehensive sequencing and array platforms, including whole exome sequencing. The purpose is to perform genomic characterization of cancer...
The National Cancer Institute (NCI) awarded an Indefinite Delivery Contract (IDC), Contract No. 75N91025D00009, to the University of Southern California (USC) to provide Genome Characterization Center (GCC) services. The purpose of this multiple-award IDC is to acquire comprehensive sequencing and array platforms, including whole exome sequencing, to support NCI's cancer genomics research programs. The GCCs will receive biomaterials from a centralized Biospecimen Processing Center and perform...
The federal contract IDV award is for Genome Characterization Center (GCC) services consisting of large-scale, high-resolution, and comprehensive sequencing and array platforms to support the National Cancer Institute's (NCI) Center for Cancer Genomics (CCG) program. The $149,974,285 multiple-award IDIQ contract was awarded to the New York Genome Center, Inc. (NYGC), a non-profit academic research institution, with a period of performance running through January 2030.
The GCC services will...
This indefinite delivery contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Infinity Biologix LLC, doing business as Sampled Division, to acquire genome characterization center (GCC) services consisting of large-scale, high-resolution, and comprehensive sequencing and array platforms, including whole exome sequencing. The contract has a ceiling value of $149,974,285 and a period of performance through January 2030.
The contract aims to support...
The National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Azenta US Inc., doing business as Brooks Life Sciences Inc., for the provision of genomic characterization services to support the NCI's Center for Cancer Genomics research programs. The IDIQ contract has a $49,832,452 ceiling value and a period of performance from August 31, 2019 through...
The federal contract IDV award HHSN261201000004I was issued by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of North Carolina at Chapel Hill (UNC-CH). This single-award Indefinite Delivery Contract has a ceiling value of $621,200 and a period of performance running from January 2010 to January 2015.
The contract's primary purpose is to provide tissue samples and associated data from various cancer types to...
This Indefinite Delivery Contract (IDC) was awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to The Broad Institute, Inc., a non-profit biomedical and genomic research organization. The $49.8 million IDC supports the NCI Genomic Characterization Centers and provides comprehensive genomic sequencing, data analysis, and other advanced computational biology services to NCI institutes and centers. Under the IDC, The Broad Institute has been awarded multiple task...
The National Cancer Institute (NCI) awarded an indefinite delivery/indefinite quantity (IDIQ) contract to The Johns Hopkins University to support the Cancer Genome Atlas (TCGA) program, which was funded under the American Recovery and Reinvestment Act (ARRA). The $159,600 multiple-award IDIQ contract, with a period of performance through March 2015, allows NCI to issue task orders for the acquisition of tissue samples and data from various cancer types for the TCGA program.
A $129,675 firm...
This indefinite delivery contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian agency, to Duke University as the prime contractor. The contract has a ceiling value of $360,000 and supports the Cancer Genome Atlas (TCGA) program, which was funded under the American Recovery and Reinvestment Act (ARRA). Under this IDC, Duke University will provide tissue samples and data from various types of cancer to contribute to the TCGA program. The contract is a task order under...
The National Cancer Institute (NCI) has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract, valued up to $149,974,285, to the University of North Carolina at Chapel Hill (UNC-CH) to provide Genome Characterization Center (GCC) services. The contract aims to acquire comprehensive genome sequencing and analysis capabilities to support NCI's cancer genomics research programs.
The GCC services include whole exome sequencing, transcriptomics, and epigenomic characterization of cancer samples. UNC-CH will receive biomaterials from a central Biospecimen Processing Center and operate high-throughput, quality-controlled pipelines to generate, analyze, and transmit the genomic data to NCI's Genomic Data Commons within 4 weeks. The 5-year IDIQ contract has a period of performance through January 2030 and may result in up to 16 individual task orders across 4 technical areas: high-throughput DNA sequencing, high-throughput RNA sequencing, epigenetic characterization, and single-cell/nuclei sequencing.